Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emidurdar - Scandion Oncology

Next Previous
Drug Profile

Emidurdar - Scandion Oncology

Alternative Names: Endovion; NS 3728; SCO-101

Latest Information Update: 14 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch
  • Developer Saniona; Scandion Oncology
  • Class Antianaemics; Antineoplastics; Bromobenzenes; Eye disorder therapies; Fluorinated hydrocarbons; Phenylurea compounds; Small molecules; Tetrazoles
  • Mechanism of Action ATP binding cassette transporter subfamily G member 2 inhibitors; Chloride channel antagonists; Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Pancreatic cancer
  • No development reported Breast cancer
  • Discontinued Age-related macular degeneration; Sickle cell anaemia

Most Recent Events

  • 26 Feb 2025 (Company) terminates a phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain due to sponsors decesion (NCT04247256)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Breast-cancer in Denmark (PO, Capsule)
  • 30 Jun 2021 Alligator Bioscience plans a clinical trial for Cancer (Combination therapy), in combination with mitazalimab and FOLFIRINOX

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top